mRNA technology is making waves with the success of the COVID-19 vaccines by Pfizer-BioNTech and Moderna. CAR-T cell therapy, a type of immunotherapy that engineers a patient’s own cells, have transformed the treatment of certain blood cancers. Now, scientists at the University of Pennsylvania have harnessed the power of both approaches in a promising experimental therapy to treat heart disease. The Penn team designed mRNAs that could turn regular T cells into therapeutic CAR-T cells inside the body to target heart fibrosis, a scarring from cardiac injury that impairs heart function. In a mouse model of heart failure, an injection...